Cat. No.: HY-N1966

(E)-Osmundacetone

2 Cited Publications

Customer Review

Based on 2 publication(s) in Google Scholar

(E)-Osmundacetone is an inhibitor of the MAPK pathway. (E)-Osmundacetone inhibits the activation of the MAPK signaling pathway and restores the expression of PPARα/ACOX1. (E)-Osmundacetone abrogates abnormal cell proliferation, migration and liver metastasis induced by PTPRO silencing in colorectal cancer cells. (E)-Osmundacetone blocks OA-RD17-mediated activation of the MAPK signaling pathway, thereby reducing macrophage proliferation and migration. (E)-Osmundacetone is applicable to relevant research on colorectal cancer.

For research use only. We do not sell to patients.

Purity: 99.81%
CAS No.: 123694-03-1
Formula: C₁₀H₁₀O₃
Molecular Weight:178.19

Storage:

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

(E)-Osmundacetone Chemical Structure

CAS No.: 123694-03-1

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Publications (2)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]

PPARα

All p38 MAPK Isoforms :

All PPAR Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	>0.28 μM Compound: 9	Cytotoxicity against human A549 cells after 96 hrs by MTT assay Cytotoxicity against human A549 cells after 96 hrs by MTT assay	[PMID: 15165144]
A549	IC₅₀	>10 μM Compound: 18	Cytotoxicity against human A549 cells after 4 days by MTT assay Cytotoxicity against human A549 cells after 4 days by MTT assay	[PMID: 24359303]
Bel-7402	IC₅₀	0.153 μM Compound: 9	Cytotoxicity against human Bel7402 cells after 96 hrs by MTT assay Cytotoxicity against human Bel7402 cells after 96 hrs by MTT assay	[PMID: 15165144]
Bel-7402	IC₅₀	4.7 μM Compound: 18	Cytotoxicity against human Bel7402 cells after 4 days by MTT assay Cytotoxicity against human Bel7402 cells after 4 days by MTT assay	[PMID: 24359303]
BGC-823	IC₅₀	0.243 μM Compound: 9	Cytotoxicity against human BGC823 cells after 96 hrs by MTT assay Cytotoxicity against human BGC823 cells after 96 hrs by MTT assay	[PMID: 15165144]
BMDM	IC₅₀	7.8 μM Compound: 1	Inhibition of M-CSF/RANKL-induced osteoclast differentiation in C57BL/6 mouse bone marrow macrophage assessed as reduction in multinucleated TRAP+ cells incubated for 6 days with fresh media replacement on day 3 and measured on day 6 by TRAP staining-base Inhibition of M-CSF/RANKL-induced osteoclast differentiation in C57BL/6 mouse bone marrow macrophage assessed as reduction in multinucleated TRAP+ cells incubated for 6 days with fresh media replacement on day 3 and measured on day 6 by TRAP staining-base	[PMID: 31257875]
HCT-8	IC₅₀	0.227 μM Compound: 9	Cytotoxicity against human HCT8 cells after 96 hrs by MTT assay Cytotoxicity against human HCT8 cells after 96 hrs by MTT assay	[PMID: 15165144]
HT-22	EC₅₀	1.5 μM Compound: 31	Neuroprotective activity against glutamate-induced cell death in mouse HT-22 cells assessed as increase in cell viability after 24 hrs by EZ-Cytox assay Neuroprotective activity against glutamate-induced cell death in mouse HT-22 cells assessed as increase in cell viability after 24 hrs by EZ-Cytox assay	[PMID: 32991171]
KB	IC₅₀	>10 μM Compound: 18	Cytotoxicity against human KB cells after 4 days by MTT assay Cytotoxicity against human KB cells after 4 days by MTT assay	[PMID: 24359303]
KETR3	IC₅₀	0.245 μM Compound: 9	Cytotoxicity against human Ketr3 cells after 96 hrs by MTT assay Cytotoxicity against human Ketr3 cells after 96 hrs by MTT assay	[PMID: 15165144]
MCF7	IC₅₀	0.141 μM Compound: 9	Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay	[PMID: 15165144]

In Vitro

(E)-osmundacetone (40 μM; 24 h) restores the expression of PPARα/ACOX1, enhances fatty acid oxidation (FAO), and reverses the promotion of proliferation, migration and liver metastasis in PTPRO-silenced SW480 and LoVo colorectal cancer (CRC) cells mediated by PTPRO silencing^[1].
(E)-Osmundacetone (10 μM) blocks the enhanced proliferation and migration of RAW264.7 macrophages induced by OA-RD17^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Real Time qPCR^[2]

Cell Line:

Keratinocytes
Concentration:

Unclear
Incubation Time:

24 h
Result:

Significantly suppressed the up-regulation of miR-632 by OA-RD17 in keratinocytes.

Chemical Information

CAS No. 123694-03-1
Appearance Solid
Molecular Weight 178.19
Formula C₁₀H₁₀O₃
Color Light yellow to yellow
SMILES

CC(/C=C/C1=CC=C(O)C(O)=C1)=O
Structure Classification
- Phenols
- Polyphenols
Initial Source
- Microorganisms
Inonotus hispidus
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Publications (2)

All

Sort by:

Journal Impact Factor

Cancer Commun (Lond)

PTPRO represses colorectal cancer tumorigenesis and progression by reprogramming fatty acid metabolism. [Abstract]

2022 Sep;42(9):848-867. PMID: 35904817
Cell Mol Biol Lett

A frog peptide provides new strategies for the intervention against skin wound healing. [Abstract]

2023 Jul 28;28(1):61. PMID: 37501100

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (561.20 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

5.6120 mL

28.0599 mL

56.1199 mL

5 mM

1.1224 mL

5.6120 mL

11.2240 mL

10 mM

0.5612 mL

2.8060 mL

5.6120 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (14.03 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.5 mg/mL (14.03 mM); Clear solution; Need ultrasonic

This protocol yields a clear solution of 2.5 mg/mL.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (278 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Dai W, et al. PTPRO represses colorectal cancer tumorigenesis and progression by reprogramming fatty acid metabolism. Cancer Commun (Lond). 2022;42(9):848-867. [Content Brief]

[2]. Li C, et al. A frog peptide provides new strategies for the intervention against skin wound healing. Cell Mol Biol Lett. 2023;28(1):61. Published 2023 Jul 28. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	5.6120 mL	28.0599 mL	56.1199 mL	140.2997 mL
	5 mM	1.1224 mL	5.6120 mL	11.2240 mL	28.0599 mL
	10 mM	0.5612 mL	2.8060 mL	5.6120 mL	14.0300 mL
	15 mM	0.3741 mL	1.8707 mL	3.7413 mL	9.3533 mL
	20 mM	0.2806 mL	1.4030 mL	2.8060 mL	7.0150 mL
	25 mM	0.2245 mL	1.1224 mL	2.2448 mL	5.6120 mL
	30 mM	0.1871 mL	0.9353 mL	1.8707 mL	4.6767 mL
	40 mM	0.1403 mL	0.7015 mL	1.4030 mL	3.5075 mL
	50 mM	0.1122 mL	0.5612 mL	1.1224 mL	2.8060 mL
	60 mM	0.0935 mL	0.4677 mL	0.9353 mL	2.3383 mL
	80 mM	0.0701 mL	0.3507 mL	0.7015 mL	1.7537 mL
	100 mM	0.0561 mL	0.2806 mL	0.5612 mL	1.4030 mL

Keywords

(E)-Osmundacetone

2 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

(E)-Osmundacetone

Cell Cycle/DNA Damage Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

Metabolism/Protease Compound Library

Natural Product Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Phenols Library

Pyroptosis Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Lung Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Microbial Metabolite Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Lipid Metabolism Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Nuclear Receptor Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Serine/Threonine Kinase Inhibitor Library

Anti-Ovarian Cancer Compound Library

Macrophage Related Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Miao Ethnicity Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Anti-Rheumatic Arthritis Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Posttranslational Modification Library

Mongolian Medicine Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) (E)-Osmundacetone

All p38 MAPK Isoforms

All PPAR Isoforms

Biological Activity

Chemical Information

Publications (2)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

(E)-Osmundacetone Related Classifications

HY-N1966 Related Classifications